CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Retrospective analysis of patients with myelodysplastic syndromes showed trends in treatment patterns that suggest: improved trend persistence with oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents beyond 6 months comparable persistence between oral decitabine and cedazuridine and intravenous/subcutaneous hypomethylating agents at early stages of therapy PRINCETON, N.J., Dec. 10, 2023 /PRNewswire/ — Taiho Oncology, Inc. announced […]
Taiho Oncology Announces Presentation of Data From a U.S. Real-Word Study of Oral Decitabine and Cedazuridine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Taiho Oncology, Inc. announced results of a U.S. real-world study of oral decitabine and cedazuridine (DEC-C) in patients with myelodysplastic.